Contributing to Healthcare Research in China Establishment of a Collaborative Lab by Shimadzu and Aidimai
Opening ceremony for the Shimadzu Aidimai Collaborative Lab
In April 2023, Shimadzu Corporation started a 3-year medium-term management plan in which “Be an innovative company that solves social issues with global partners” is treated as a basic policy. Shimadzu is strengthening its collaboration with global partners through the overseas sites in the four domains of healthcare, green transformation, materials, and industry.
In March of this year, Shimadzu (China) Co., Ltd. (hereafter SSL), which oversees business operations in China, signed a strategic cooperative agreement with Nanjing Aidimai Technology Co., Ltd. (hereafter Aidimai), a company that handles clinical tests and reagents. The two companies have established the Shimadzu Aidimai Collaborative Lab with the aim of popularizing chromatography technology in the clinical field and developing clinical testing systems.
Aidimai’s Expertise in the Clinical Field
Aidimai, which was established in 2019, has expertise in clinical tests and the manufacturing of related reagents. The company has offices in Jiangsu Province, Chongqing City, and Hunan Province, and works cooperatively with a number of examination agencies and businesses in and outside of China.
Aidimai’s pretreatment*1 technology and instruments using magnetic beads are widely utilized for therapeutic drug monitoring (TDM), and the measurement of vitamins and hormones in blood, as well as for the purification and analysis of nucleic acid pharmaceuticals and antibody pharmaceuticals.
- *1: In this process, magnetic beads linked to antibodies are utilized to selectively capture or separate out specific molecules and substances in a sample. This heightens the efficiency of pretreatment and analysis, and improves purification.
Shimadzu Aidimai Collaborative Lab
At this laboratory, in future, Aidimai’s automatic magnetic beads pretreatment unit will be combined with Shimadzu’s liquid chromatographs (LC) and mass spectrometers (MS) to develop high-precision and high-efficiency clinical testing systems and solutions for TDM, and analysis targeting vitamins, hormones, and catecholamines*2.
- *2: This is a general term for organic amines existing primarily in the brain, adrenal medulla, and sympathetic nerves. Examples include dopamine, noradrenaline, and adrenaline.
Comments by Both Companies
At the opening ceremony, both companies made the following statements.
Gongming Shi, Aidimai Chairman/General Manager
The establishment of the Shimadzu Aidimai Collaborative Lab is based on many years of belief of both Shimadzu and Aidimai: “Move forward together, remaining true to our original intention.”
We plan to more efficiently integrate the features of the technologies and products of both companies, as we respond to the various needs of customers with respect to chromatography and mass spectrometry in the clinical field.
Jiaxiang Hu, General Manager of the Marketing Department, Analytical & Measuring Instruments Division, SSL
The establishment of this laboratory with Aidimai represents a new milestone in satisfying needs in the clinical field, aiming at the collaborative development of even higher level chromatography methods.
Shimadzu will maintain a sincere attitude in regard to development, collaboration, and diversification. In addition, we will continue to strive to achieve precision medicine together with our excellent partners, to contribute to people’s health.
Page Title and URL Copied.